Today: 7 February 2026
Subscribe
Browse Category

NYSE:SMFG News 27 November 2025

Sumitomo Mitsui Financial Group (SMFG) Stock Rises as Japan’s Bank Rally Extends – November 27, 2025 Update

Sumitomo Mitsui Financial Group (SMFG) Stock Rises as Japan’s Bank Rally Extends – November 27, 2025 Update

Published: November 27, 2025 Sumitomo Mitsui Financial Group, Inc. (TSE: 8316, NYSE: SMFG) extended its November rally on Thursday as Japanese equities surged again and bank stocks led gains on the Tokyo market. According to late-session data, Sumitomo Mitsui Financial Group (SMFG) shares in Tokyo closed around ¥4,684, up roughly 2.2% on the day, with about 2.8 million shares changing hands.Investing.com+1 That move adds to a strong two‑week run in which the stock has climbed about 10%, rising in eight of the last ten trading days.StockInvest On Wall Street, the group’s New York–listed ADRs last ended Wednesday’s session at $17.84,
27 November 2025
···

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop